Compare Stocks → Urgent: Protect Your Investments from a Chinese Invasion (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADMPNASDAQ:CNATNASDAQ:ONCSNASDAQ:ORMPNASDAQ:TORC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMPAdamis Pharmaceuticals$1.28$0.75▼$26.18$7.26M1.27811,695 shs119,800 shsCNATConatus Pharmaceuticals$0.40$1.00$0.23▼$1.07$13.27M1.841.28 million shs2,011 shsONCSOncoSec Medical$0.52$0.18▼$20.46$1.26M1.992.22 million shs52.49 million shsORMPOramed Pharmaceuticals$2.91+3.2%$2.90$1.67▼$5.25$117.91M1.83182,082 shs176,495 shsTORCresTORbio$2.33+4.0%$12.16$0.86▼$10.50$84.94M2.431.15 million shs614,658 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMPAdamis Pharmaceuticals0.00%0.00%0.00%0.00%-90.37%CNATConatus Pharmaceuticals0.00%+21.21%+26.98%+29.03%-65.81%ONCSOncoSec Medical0.00%0.00%0.00%0.00%-87.73%ORMPOramed Pharmaceuticals+3.68%-4.73%-20.56%+20.51%+29.95%TORCresTORbio+4.02%+14.78%-5.67%+32.39%-60.64%Urgent: Protect Your Investments from a Chinese Invasion (Ad)An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.Click here to get my exclusive report NOW >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACNATConatus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ATORCresTORbioN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMPAdamis PharmaceuticalsN/AN/AN/AN/ACNATConatus PharmaceuticalsN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/ATORCresTORbioN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMPAdamis Pharmaceuticals$4.76M0.00N/AN/A($1.26) per share0.00CNATConatus Pharmaceuticals$21.72M0.61N/AN/A$0.53 per share0.75ONCSOncoSec MedicalN/AN/AN/AN/A$3.42 per shareN/AORMPOramed Pharmaceuticals$1.34M87.99N/AN/A$4.04 per share0.72TORCresTORbioN/AN/AN/AN/A$2.24 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMPAdamis Pharmaceuticals-$26.48MN/A0.00N/AN/A-502.73%-420.53%-256.87%N/ACNATConatus Pharmaceuticals-$11.39MN/AN/A∞N/A-52.42%-48.22%-39.32%N/AONCSOncoSec Medical-$34.18M-$15.29N/AN/AN/AN/A-868.29%-160.61%N/AORMPOramed Pharmaceuticals$5.53M$0.1420.79∞N/A-747.02%-7.15%-5.70%5/9/2024 (Estimated)TORCresTORbio-$82.74M-$2.41N/AN/AN/AN/A-78.12%-71.63%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/ACNATConatus PharmaceuticalsN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/ATORCresTORbioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMPAdamis PharmaceuticalsN/A0.230.19CNATConatus PharmaceuticalsN/A16.2816.28ONCSOncoSec MedicalN/A0.890.89ORMPOramed PharmaceuticalsN/A3.063.06TORCresTORbioN/A20.6920.69OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMPAdamis Pharmaceuticals38.55%CNATConatus Pharmaceuticals15.20%ONCSOncoSec Medical8.69%ORMPOramed Pharmaceuticals12.73%TORCresTORbio46.19%Insider OwnershipCompanyInsider OwnershipADMPAdamis Pharmaceuticals1.30%CNATConatus Pharmaceuticals11.30%ONCSOncoSec Medical1.32%ORMPOramed Pharmaceuticals12.00%TORCresTORbio11.80%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADMPAdamis Pharmaceuticals119.36 million9.24 millionOptionableCNATConatus Pharmaceuticals3033.17 millionN/ANot OptionableONCSOncoSec Medical404.55 million4.49 millionNot OptionableORMPOramed Pharmaceuticals1240.52 million35.66 millionOptionableTORCresTORbioN/A36.45 millionN/ANot OptionableTORC, ADMP, CNAT, ORMP, and ONCS HeadlinesSourceHeadlineAdicet Bio Inc (ACET)investing.com - January 30 at 1:54 PMTargeting the biology of aging with mTOR inhibitors - Nature.comnews.google.com - May 4 at 10:20 PMPARP7 Inhibitor RBN-2397 Has Tolerable Safety Profile in Solid ... - OncLivenews.google.com - March 17 at 7:14 PMMichelle Chaka Joins Torc as Senior Vice President, Safety and Regulatoryfinance.yahoo.com - February 24 at 7:08 PMTorc names regulatory, safety SVPvirginiabusiness.com - February 24 at 7:08 PMGlobal AI in Life Extension Market Poised for Growth Amidst Rising Demand for Prolonging Life (2022 - 2030) - openPRnews.google.com - February 8 at 10:13 AMPhenotypic Presentations and the Management of Moderate to ... - Healionews.google.com - January 31 at 2:37 PMAerovate Therapeutics Appoints Donald Santel To Its Board of ... - Marketscreener.comnews.google.com - January 23 at 3:41 PMAerovate Therapeutics Appoints Donald Santel To Its Board of ... - GlobeNewswirenews.google.com - January 23 at 8:44 AMTinOne Resources Inc. (TORC.V)finance.yahoo.com - January 10 at 8:39 AMresTORbio IPO on Deck, Less than a Year After Licensing Clinical ... - Equities Newsnews.google.com - December 16 at 11:48 PMresTORbio Shows Positive Phase 2b Data in Respiratory Tract Infections - Equities Newsnews.google.com - December 12 at 10:01 PMBrian Kennedy – validating aging interventions and why rapamycin is the gold standard - Longevity.Technologynews.google.com - November 3 at 9:25 PMTORC Investments, LLCgwinnettdailypost.com - October 6 at 9:57 AMCelebrity Strategy Consultant Predicts What Will Be The Most Impactful Area In The Pharmaceutical Industry - Forbesforbes.com - September 19 at 2:52 PMFast-growing cancer cell therapy developer Adicet Bio takes more space - San Francisco Business Times - The Business Journalsbizjournals.com - September 12 at 7:31 PMCellular Immunotherapy Market Study 2022-2030 by Current and Upcoming Trends, Opportunities, Size, Trends and - openPRopenpr.com - September 6 at 7:33 AMFor preventing aging, some decades old drugs? - BioWorld Onlinebioworld.com - July 18 at 10:42 PMForm DEF 14A BiomX Inc. For: Aug 24 - StreetInsider.comstreetinsider.com - July 8 at 2:10 AMTerns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer - GuruFocus.comgurufocus.com - June 21 at 9:11 PMThe Best Hand Creams - Don't Waste Your Moneydontwasteyourmoney.com - June 18 at 1:34 PMTime Passages: Bruce Goldsmith out at Jim Wilson's gene therapy biotech; Flagship reveals Michael Severino's CEO gig - Endpoints Newsendpts.com - June 3 at 11:42 PMTerns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer - KULR-TVkulr8.com - June 3 at 11:42 PMTerns Pharmaceuticals Inc. (TERN) Appoints Kerry Russell as Chief Medical Officer - StreetInsider.comstreetinsider.com - June 1 at 9:12 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAdamis PharmaceuticalsNASDAQ:ADMPAdamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.Conatus PharmaceuticalsNASDAQ:CNATConatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.OncoSec MedicalNASDAQ:ONCSOncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.Oramed PharmaceuticalsNASDAQ:ORMPOramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.resTORbioNASDAQ:TORCAdicet Bio, Inc. is a biotechnology company which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.